Pomerantz LLP is investigating Regeneron Pharmaceuticals for potential securities fraud after the company announced that its Phase 3 trial for a melanoma drug combo failed to meet key goals. The news caused Regeneron's stock to drop nearly 10%. The investigation will determine if Regeneron or its executives engaged in unlawful practices. Investors affected by the stock decline may join a class action lawsuit.
Regeneron Pharmaceuticals announced it will present new clinical data and research on treatments for metabolic diseases, eye conditions, and rare diseases at the ADA and ENDO medical meetings in June 2026. Highlights include Phase 2 trial results on ...
CytomX Therapeutics has expanded its collaboration with Regeneron Pharmaceuticals to develop conditionally-activated bispecific cancer therapies using their PROBODY and Veloci-Bi platforms. CytomX will receive a $37 million payment for two new target...
